Category Archives: Global

Europe Approves First Medicine for Castleman's Disease

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Sylvant (siltuximab) for adult patients with multicentric Castleman’s disease.
Also posted in Europe, Orphan Drugs, Regulatory | Tagged , , , | 2 Comments

Drug Discovery CRO Sector to Thrive in Europe

The European pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery, writes Faiz Kermani. The European pharmaceutical industry accounts for nearly 40% of the global industry’s R&D investment. Although  companies are responding to current pressures by closing R&D sites, they still need to support their ongoing drug-development projects […]
Also posted in Europe, Events, Guest Blog, R&D | Tagged , , , | Leave a comment

Europe: EFPIA Campaign Calls for Integrated Life Sciences Strategy

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a social media campaign calling for an integrated life sciences  strategy for the EU. The #HealthyEU Health and Growth campaign will outline the opportunities and threats faced by patients and the healthcare sector today, and provide evidence and facts to inform healthcare debates in the run […]
Also posted in E-Media, Europe, Events, multimedia, Regulatory, social media, Strategy | Tagged , , , , , | Leave a comment

Japan's Schizophrenia Market to Double by 2022, Says Report

Japan’s schizophrenia treatment market value will see revenues doubling from $0.7 billion in 2012 to $1.4 billion by 2022 (a Compound Annual Growth Rate [CAGR] of 7.74%), says a new report from  GlobalData.
Also posted in Market Access | Tagged , , , | Leave a comment

Weak IP Protection Threatens Asia-Pac Biotech Boom

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital  investments in biotechnology. According to research and consulting firm GlobalData, healthcare private equity investment in APAC increased by 125.8% between 2011 and 2013,  whereas deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 […]
Also posted in Deals, Emerging Markets, IP | Tagged , , , | Leave a comment
  • Categories

  • Meta